SEC Tracker
Get the app

Arcutis Biotherapeutics ARQT

Todd Watanabe (CEO) sold 40,000 ARQT at $25.03, worth $1M, under a 10b5-1 plan

Form
4
Filed
Importance
Routine
  1. Sold 40,000 shares at $25.0258
  2. Held 806,440 shares directly
  3. Indirectly held 25,410 shares by trust
  4. Indirectly held 57,358 shares by LLC

Written from the Form 4 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Arcutis Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Ligand Pharmaceuticals LGND public float $1.6B, Jun 30, 2025
  2. Ocular Therapeutix OCUL public float $1.6B, Jun 30, 2025
  3. Arrowhead Pharmaceuticals ARWR public float $1.4B, Mar 31, 2025, over 18 months old
  4. Sarepta Therapeutics SRPT public float $1.7B, Jun 30, 2025
  5. Adaptive Biotechnologies ADPT public float $1.4B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.